Jun-Ling Li

List of Publications by Year
in descending order

39	519	932766	887659
papers	citations	10	17
		h-index	g-index

40	40	40	730
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study. Journal of Cancer Research and Clinical Oncology, 2022, 148, 3081-3089.	1.2	9
2	Apatinib as maintenance therapy following standard firstâ€line chemotherapy in extensive disease small cell lung cancer: A phase <scp>II</scp> singleâ€arm trial. Thoracic Cancer, 2022, 13, 557-562.	0.8	5
3	Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastasesâ€”a multicenter retrospective study. BMC Medicine, 2022, 20, 12.	2.3	16
4	Specific HER2 Exon 20 Gly776 Deletion-Insertions in Non-Small Cell Lung Cancer: Structural Analysis and Sensitivity to HER2-Targeted Tyrosine Kinase Inhibitors. Frontiers in Pharmacology, 2022, 13, 806737.	1.6	3
5	Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in EGFR-Mutated Lung Adenocarcinoma: A Real-World Study in Chinese Patients. Cancer Management and Research, 2022, Volume 14, 863-873.	0.9	4
6	Clinical significance of ALDH1A1 expression and its association with E-cadherin and N-cadherin in resected large cell neuroendocrine carcinoma. Translational Oncology, 2022, 19, 101379.	1.7	1
7	<scp>ASCL1</scp> and <scp>DLL3</scp> expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the <scp>National Cancer Center of China</scp>. Thoracic Cancer, 2022, 13, 338-345.	0.8	5
8	Efficacy of first-line treatments in the elderly and non-elderly patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: a network meta-analysis. BMC Cancer, 2022, 22, 514.	1.1	1
9	Disease monitoring of epidermal growth factor receptor (EGFR)â€mutated nonâ€smallâ€cell lung cancer patients treated with tyrosine kinase inhibitors via <scp>EGFR</scp> status in circulating tumor <scp>DNA</scp>. Thoracic Cancer, 2022, 13, 2201-2209.	0.8	4
10	Clinicopathological features and prognostic analysis of 247 small cell lung cancer with limited-stage after surgery. Human Pathology, 2021, 108, 84-92.	1.1	6
11	Clinicopathological features and prognostic implications of <scp>ASCL1</scp> expression in surgically resected small cell lung cancer. Thoracic Cancer, 2021, 12, 40-47.	0.8	6
12	Survival and pretreatment prognostic factors for extensiveâ€stage small cell lung cancer: A comprehensive analysis of <scp>358</scp> patients. Thoracic Cancer, 2021, 12, 1943-1951.	0.8	26
13	Concurrent chemotherapy and firstâ€generation epidermal growth factor receptor (EGFR)â€tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as firstâ€line treatment in advanced lung adenocarcinoma harboring an EGFR mutation. Thoracic Cancer, 2021, 12, 2233-2240.	0.8	1
14	Efficacy and safety profile of combining programmed cell deathâ€1 (<scp>PD</scp>â€1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic nonâ€small cell lung cancer (<scp>NSCLC</scp>). Thoracic Cancer, 2021, 12, 2360-2368.	0.8	4
15	Pyrotinib in HER2 heterogeneously mutated or amplified advanced non-small cell lung cancer patients: a retrospective real-world study (PEARL). Journal of the National Cancer Center, 2021, 1, 139-146.	3.0	7
16	Study protocol: A singleâ€arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with firstâ€line immunotherapy. Thoracic Cancer, 2021, 12, 2825-2828.	0.8	7
17	Aperture: alignment-free detection of structural variations and viral integrations in circulating tumor DNA. Briefings in Bioinformatics, 2021, 22, .	3.2	3
18	Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma. Thoracic Cancer, 2021, 12, 2585-2593.	0.8	12

#	Article	IF	Citations
19	Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations. Thoracic Cancer, 2021, 12, 2924-2932.	0.8	9
20	YAP1 protein expression has variant prognostic significance in small cell lung cancer (SCLC) stratified by histological subtypes. Lung Cancer, 2021, 160, 166-174.	0.9	10
21	ARID1A serves as a receivable biomarker for the resistance to EGFR-TKIs in non-small cell lung cancer. Molecular Medicine, 2021, 27, 138.	1.9	8
22	Efficacy of dacomitinib in patients with <scp>EGFR</scp>â€mutated <scp>NSCLC</scp> and brain metastases. Thoracic Cancer, 2021, 12, 3407-3415.	0.8	14
23	Clinical outcome, longâ€term survival and tolerability of sequential therapy of firstâ€line crizotinib followed by alectinib in advanced ALK + NSCLC : A multicenter retrospective analysis in China. Thoracic Cancer, 2021, , .	0.8	3
24	Front-Line Therapy in EGFR Exon 19 Deletion and 21 Leu858Arg Mutations in Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-15.	0.5	7
25	Comparative study of clinicopathological characteristics and prognosis between combined and pure small cell lung cancer (SCLC) after surgical resection. Thoracic Cancer, 2020, 11, 2782-2792.	0.8	15
26	Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2427-2433.	1.2	41
27	Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib. Targeted Oncology, 2019, 14, 335-342.	1.7	28
28	Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations. Thoracic Cancer, 2019, 10, 1461-1468.	0.8	11
29	Clinical features and outcomes of ALK rearranged nonâ€small cell lung cancer with primary resistance to crizotinib. Thoracic Cancer, 2019, 10, 1213-1219.	0.8	5
30	Efficacy of Crizotinib for Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Patients with Brain Metastasis: A Multicenter, Retrospective Study in China. Targeted Oncology, 2019, 14, 325-333.	1.7	9
31	Data from real world to evaluate the efficacy of osimertinib in non-small cell lung cancer patients with central nervous system metastasis. Clinical and Translational Oncology, 2019, 21, 1424-1431.	1.2	19
32	Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. , 2019, 7, 341.		126
33	Real-World Data Of Osimertinib In Patients With Pretreated Non-Small Cell Lung Cancer: A Retrospective Study . Cancer Management and Research, 2019, Volume 11, 9243-9251.	0.9	16
34	Response to crizotinib in advanced ALK -rearranged non-small cell lung cancers with different ALK -fusion variants. Lung Cancer, 2018, 118, 128-133.	0.9	50
35	Evaluation of calculating carboplatin dosage in carboplatinâ€“pemetrexed therapy as the firstâ€line therapy for Chinese patients with advanced lung adenocarcinoma. Thoracic Cancer, 2018, 9, 400-407.	0.8	3
36	Real world study of the continuation of bevacizumab beyond disease progression after firstâ€line treatment containing bevacizumab in Chinese patients with advanced nonâ€small cell lung cancer. Thoracic Cancer, 2018, 9, 1716-1724.	0.8	3

#	Article	IF	Citations
37	Real world study of regimen containing bevacizumab as firstâ€line therapy in Chinese patients with advanced nonâ€small cell lung cancer. Thoracic Cancer, 2018, 9, 805-813.	0.8	10
38	Gemcitabine combined with cisplatin as adjuvant chemotherapy for nonâ€small cell lung cancer: <scp>A</scp> retrospective analysis. Thoracic Cancer, 2017, 8, 482-488.	0.8	7
39	P3.04-007 A Prospective Study of Apatinib in Advanced Small Cell Lung Cancer Patients Failed from Two or More Lines of Chemotherapy. Journal of Thoracic Oncology, 2017, 12, S2287.	0.5	5